Top View
- Poisons and Drugs Amendment Act 2000
- The Misuse of Drugs Regulations (Northern Ireland) 2002
- Effects of a New Steroidal Aromatase Inhibitor, TZA-2237, And/Or Chlormadinone Acetate on Hormone-Induced and Spontaneous Canine Benign Prostatic Hyperplasia
- Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
- Pharmaceuticals Appendix
- United States Patent (19) 11 Patent Number: 5,861,389 Radlmaier Et Al
- Information to Users
- Antitumoral and Endocrine Effects of (+)-Vorozole in Rats Bearing Dimethylbenzanthracene-Induced Mammary Tumors Roland De Coster,1 Robert F
- Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
- (12) United States Patent (10) Patent No.: US 9,345,766 B2 Zhang Et Al
- Aromatase Inhibitors in Men: Effects and Therapeutic Options Willem De Ronde1 and Frank H De Jong2*
- (12) United States Patent (Io) Patent No.: US 9,526,824 B2 Ferrari Et Al
- Supplementary Materials
- Pharmaabkommen A1 E
- Effects of a New Steroidal Aromatase Inhibitor, TZA-2237, And/Or Chlormadinone Acetate on Hormone-Induced and Spontaneous Canine Benign Prostatic Hyperplasia
- Exercise Therapies for Preventing Or Treating Aromatase Inhibitor-Induced Musculoskeletal Symptoms in Early Breast Cancer (Protocol)
- Kriterien Zur Bestimmung Der Zweckmäßigen Vergleichstherapie Und
- Customs Tariff - Schedule Xxi - 1
- Wo 2007/044693 A2
- Exemestane, a New Steroidal Aromatase Inhibitor of Clinical Relevance$
- Somatic and Psychological Effects of Low-Dose Aromatase Inhibition in Men with Obesity-Related Hypogonadotropic Hypotestosterone
- Harmonized Tariff Schedule of the United States (2006) (Rev
- General Agreement on Tariffs Andtrade
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Clinical Utility of Exemestane in the Treatment of Breast Cancer
- Aromatase Inhibitors and Their Use in the Sequential Setting
- UWHC IV Infusion Mini Manual
- (12) Patent Application Publication (10) Pub. No.: US 2017/0056347 A1 Glick Et Al
- (Faslodex) for Metastatic Breast Cancer
- Misuse of Drugs Amendment Regulations 2017
- Controlled Drugs List
- Pharmaceutical Appendix to the Tariff Schedule 2
- ― D04 - 1 ― 医学中央雑誌刊行会・医学用語シソーラス 第9版( 2019) カテゴリー別リスト
- Compositions for Treating Breast Cancer
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Pharmaceutical Appendix to the Tariff Schedule 2
- Medicines Regulations 1984 (SR 1984/143)
- Harmonized Tariff Schedule of the United States (2006) (Rev
- 1111111111111111111Imnumu
- APPLICANT V. EUROPEAN PATENT OFFICE
- L:\0900\0900PHARMAPPX .Wpd
- United States Patent 19 11 Patent Number: 5,798.338 Backensfeld Et Al
- Table of Contents
- HDAC Inhibitors and Hormone Targeted Drugs for the Treatment of Cancer
- Effects of a New Steroidal Aromatase Inhibitor, TZA-2237, And/Or Chlormadinone Acetate on Hormone-Induced and Spontaneous Canine Benign Prostatic Hyperplasia
- Aromatase Inhibitors and Enzyme Stability